Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Minority Interest (2016 - 2019)

Spero Therapeutics (SPRO) has disclosed Minority Interest for 4 consecutive years, with $355000.0 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Minority Interest changed 0.0% year-over-year to $355000.0, compared with a TTM value of $355000.0 through Sep 2019, changed 0.0%, and an annual FY2018 reading of $355000.0, changed 0.0% over the prior year.
  • Minority Interest was $355000.0 for Q3 2019 at Spero Therapeutics, roughly flat from $355000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $6.4 million in Q2 2017 and bottomed at -$3.8 million in Q4 2016.
  • Average Minority Interest over 4 years is $526636.4, with a median of $355000.0 recorded in 2017.
  • The sharpest move saw Minority Interest skyrocketed 109.32% in 2017, then tumbled 94.45% in 2018.
  • Year by year, Minority Interest stood at -$3.8 million in 2016, then soared by 109.32% to $355000.0 in 2017, then changed by 0.0% to $355000.0 in 2018, then changed by 0.0% to $355000.0 in 2019.
  • Business Quant data shows Minority Interest for SPRO at $355000.0 in Q3 2019, $355000.0 in Q2 2019, and $355000.0 in Q1 2019.